{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:39:50Z","timestamp":1787312390060,"version":"build-2736575974"},"reference-count":103,"publisher":"Portland Press Ltd.","issue":"14","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,7,15]]},"abstract":"<jats:p>The KDIGO definition of chronic kidney disease (CKD) allowed a more detailed characterization of CKD causes, epidemiology and consequences. The picture that has emerged is worrisome from the point of view of translation. CKD was among the fastest growing causes of death in the past 20 years in age-adjusted terms. The gap between recent advances and the growing worldwide mortality appears to result from sequential roadblocks that limit the flow from basic research to clinical development (translational research type 1, T1), from clinical development to clinical practice (translational research T2) and result in deficient widespread worldwide implementation of already available medical advances (translational research T3). We now review recent advances and novel concepts that have the potential to change the practice of nephrology in order to improve the outcomes of the maximal number of individuals in the shortest possible interval. These include: (i) updating the CKD concept, shifting the emphasis to the identification, risk stratification and care of early CKD and redefining the concept of aging-associated \u2018physiological\u2019 decline of renal function; (ii) advances in the characterization of aetiological factors, including challenging the concept of hypertensive nephropathy, the better definition of the genetic contribution to CKD progression, assessing the role of the liquid biopsy in aetiological diagnosis and characterizing the role of drugs that may be applied to the earliest stages of injury, such as SGLT2 inhibitors in diabetic kidney disease (DKD); (iii) embracing the complexity of CKD as a network disease and (iv) exploring ways to optimize implementation of existing knowledge.<\/jats:p>","DOI":"10.1042\/cs20160395","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T20:10:36Z","timestamp":1498853436000},"page":"1617-1629","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Translational science in chronic kidney disease"],"prefix":"10.1042","volume":"131","author":[{"given":"Maria\u00a0Dolores","family":"Sanchez-Ni\u00f1o","sequence":"first","affiliation":[{"name":"IIS-Fundacion Jimenez Diaz, School of Medicine, Universidad Autonoma de Madrid; Fundacion Renal I\u00f1igo Alvarez de Toledo-IRSIN and REDINREN, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00a0B.","family":"Sanz","sequence":"additional","affiliation":[{"name":"IIS-Fundacion Jimenez Diaz, School of Medicine, Universidad Autonoma de Madrid; Fundacion Renal I\u00f1igo Alvarez de Toledo-IRSIN and REDINREN, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian\u00a0M.","family":"Ramos","sequence":"additional","affiliation":[{"name":"IIS-Fundacion Jimenez Diaz, School of Medicine, Universidad Autonoma de Madrid; Fundacion Renal I\u00f1igo Alvarez de Toledo-IRSIN and REDINREN, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ruiz-Ortega","sequence":"additional","affiliation":[{"name":"IIS-Fundacion Jimenez Diaz, School of Medicine, Universidad Autonoma de Madrid; Fundacion Renal I\u00f1igo Alvarez de Toledo-IRSIN and REDINREN, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[{"name":"IIS-Fundacion Jimenez Diaz, School of Medicine, Universidad Autonoma de Madrid; Fundacion Renal I\u00f1igo Alvarez de Toledo-IRSIN and REDINREN, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2017,6,30]]},"reference":[{"key":"2021113010580956800_B1","first-page":"1","article-title":"KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","journal-title":"Kidney Int. Suppl."},{"key":"2021113010580956800_B2","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1681\/ASN.2015050542","article-title":"CKD prevalence varies across the European general population","volume":"27","author":"Br\u00fcck","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113010580956800_B3","volume-title":"2014 Annual Data Report: Epidemiology of Kidney Disease in the United States","author":"United States Renal Data System","year":"2014"},{"key":"2021113010580956800_B4","doi-asserted-by":"crossref","first-page":"e72860","DOI":"10.1371\/journal.pone.0072860","article-title":"The gap between estimated incidence of end-stage renal disease and use of therapy","volume":"8","author":"Anand","year":"2013","journal-title":"PLoS ONE"},{"key":"2021113010580956800_B5","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(14)61601-9","article-title":"Worldwide access to treatment for end-stage kidney disease: a systematic review","volume":"385","author":"Liyanage","year":"2015","journal-title":"Lancet"},{"key":"2021113010580956800_B6","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0140-6736(14)60384-6","article-title":"Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure","volume":"383","author":"Ortiz","year":"2014","journal-title":"Lancet"},{"key":"2021113010580956800_B7","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(16)00033-4","article-title":"Clinical management of the uraemic syndrome in chronic kidney disease","volume":"4","author":"Vanholder","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2021113010580956800_B8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","author":"GBD 2013 Mortality and Causes of Death Collaborators","year":"2015","journal-title":"Lancet"},{"key":"2021113010580956800_B9","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S2213-8587(15)00092-3","article-title":"Humble kidneys predict mighty heart troubles","volume":"3","author":"Ortiz","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2021113010580956800_B10","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2021113010580956800_B11","volume-title":"2016 Annual Data Report: Epidemiology of Kidney Disease in the United States","author":"United States Renal Data System","year":"2016"},{"key":"2021113010580956800_B12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.nefro.2015.10.020","article-title":"The Spanish Renal Registry: 2013 report and evolution from 2007-2013","volume":"36","author":"Mart\u00edn Escobar","year":"2016","journal-title":"Nefrologia"},{"key":"2021113010580956800_B13","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1016\/S0140-6736(16)30446-9","article-title":"Mortality decrease according to socioeconomic groups during the economic crisis in Spain: a cohort study of 36 million people","volume":"388","author":"Regidor","year":"2016","journal-title":"Lancet"},{"key":"2021113010580956800_B14","year":"2016"},{"key":"2021113010580956800_B15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfu142","article-title":"Translational nephrology: what translational research is and a bird\u2019s-eye view on translational research in nephrology","volume":"8","author":"Ortiz","year":"2015","journal-title":"Clin. Kidney J."},{"key":"2021113010580956800_B16","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/453840a","article-title":"Translational research: crossing the valley of death","volume":"453","author":"Butler","year":"2008","journal-title":"Nature"},{"key":"2021113010580956800_B17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/jama.2007.26","article-title":"The meaning of translational research and why it matters","volume":"299","author":"Woolf","year":"2008","journal-title":"JAMA"},{"key":"2021113010580956800_B18","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1681\/ASN.2008060621","article-title":"Hypertension-associated kidney disease: perhaps no more","volume":"19","author":"Freedman","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113010580956800_B19","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2021113010580956800_B20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2021113010580956800_B21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/ckj\/sfv115","article-title":"Thrombotic microangiopathy: expanding genetic, clinical and therapeutic spectra and the need for worldwide implementation of recent advances","volume":"8","author":"Sanchez-Ni\u00f1o","year":"2015","journal-title":"Clin. Kidney J."},{"key":"2021113010580956800_B22","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(16)32051-7","article-title":"Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries","volume":"389","author":"Ghinea","year":"2017","journal-title":"Lancet"},{"key":"2021113010580956800_B23","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/S0140-6736(16)31467-2","article-title":"Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015","volume":"388","author":"GBD 2015 SDG Collaborators","year":"2016","journal-title":"Lancet"},{"key":"2021113010580956800_B24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/ckj\/sfv035","article-title":"2012 ERA-EDTA Registry Annual Report: cautious optimism on outcomes, concern about persistent inequalities and data black-outs","volume":"8","author":"Gonzalez-Espinoza","year":"2015","journal-title":"Clin. Kidney J."},{"key":"2021113010580956800_B25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/ckj\/sfv151","article-title":"Renal replacement therapy in Europe: a summary of the 2013 ERA-EDTA Registry Annual Report with a focus on diabetes mellitus","volume":"9","author":"Kramer","year":"2016","journal-title":"Clin. Kidney J."},{"key":"2021113010580956800_B26","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00774-015-0706-y","article-title":"Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate","volume":"34","author":"Gonz\u00e1lez-Parra","year":"2016","journal-title":"J. Bone Miner. Metab."},{"key":"2021113010580956800_B27","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Guti\u00e9rrez","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"2021113010580956800_B28","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J. Clin. Invest."},{"key":"2021113010580956800_B29","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1172\/JCI83470","article-title":"FGF23 signaling impairs neutrophil recruitment and host defense during CKD","volume":"126","author":"Rossaint","year":"2016","journal-title":"J. Clin. Invest."},{"key":"2021113010580956800_B30","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ckj\/sfx002","article-title":"Urinary-peptide based classifier CKD273: towards clinical application in chronic kidney disease","volume":"10","author":"Pontillo","year":"2017","journal-title":"Clin. Kidney J."},{"key":"2021113010580956800_B31","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1681\/ASN.2014050423","article-title":"Diagnosis and prediction of CKD progression by assessment of urinary peptides","volume":"26","author":"Schanstra","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113010580956800_B32","first-page":"gfw239","article-title":"A urinary proteome-based classifier for the early detection of decline in glomerular filtration","author":"Pontillo","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"2021113010580956800_B33","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1210\/er.2013-1079","article-title":"Molecular basis of klotho: from gene to function in aging","volume":"36","author":"Xu","year":"2015","journal-title":"Endocr. Rev."},{"key":"2021113010580956800_B34","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1681\/ASN.2013111209","article-title":"The kidney is the principal organ mediating klotho effects","volume":"25","author":"Lindberg","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113010580956800_B35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/36285","article-title":"Mutation of the mouse klotho gene leads to a syndrome resembling ageing","volume":"390","author":"Kuro-o","year":"1997","journal-title":"Nature"},{"key":"2021113010580956800_B36","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/ndt\/gfs426","article-title":"Klotho, phosphate and inflammation\/ageing in chronic kidney disease","volume":"27","author":"Izquierdo","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"2021113010580956800_B37","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1096\/fj.10-167056","article-title":"Dietary and genetic evidence for enhancing glucose metabolism and reducing obesity by inhibiting klotho functions","volume":"25","author":"Ohnishi","year":"2011","journal-title":"FASEB J."},{"key":"2021113010580956800_B38","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1681\/ASN.2009121311","article-title":"Klotho deficiency causes vascular calcification in chronic kidney disease","volume":"22","author":"Hu","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113010580956800_B39","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1681\/ASN.2011121175","article-title":"Normal and pathologic concentrations of uremic toxins","volume":"23","author":"Duranton","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113010580956800_B40","doi-asserted-by":"crossref","first-page":"e1644","DOI":"10.1038\/cddis.2015.1","article-title":"Albumin-induced apoptosis of tubular cells is modulated by BASP1","volume":"6","author":"Sanchez-Ni\u00f1o","year":"2015","journal-title":"Cell Death Dis."},{"key":"2021113010580956800_B41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nrneph.2010.174","article-title":"Tubular toxicity of proteinuria","volume":"7","author":"Baines","year":"2011","journal-title":"Nat. Rev. Nephrol."},{"key":"2021113010580956800_B42","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1681\/ASN.2010101073","article-title":"The inflammatory cytokines TWEAK and TNF\u03b1 reduce renal klotho expression through NF\u03baB","volume":"22","author":"Moreno","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113010580956800_B43","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2012.16817","article-title":"Age and association of kidney measures with mortality and end-stage renal disease","volume":"308","author":"Hallan","year":"2012","journal-title":"JAMA"},{"key":"2021113010580956800_B44","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/sj.ki.5000270","article-title":"Progression of kidney dysfunction in the community-dwelling elderly","volume":"69","author":"Hemmelgarn","year":"2006","journal-title":"Kidney Int."},{"key":"2021113010580956800_B45","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/MNH.0000000000000266","article-title":"Imaging the kidney using magnetic resonance techniques: structure to function","volume":"25","author":"Mahmoud","year":"2016","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"2021113010580956800_B46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1148\/radiol.2016160566","article-title":"Noninvasive assessment of renal fibrosis with magnetization transfer MR imaging: validation and evaluation in murine renal artery stenosis","volume":"283","author":"Jiang","year":"2017","journal-title":"Radiology"},{"key":"2021113010580956800_B47","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.kint.2016.06.042","article-title":"Ultrasound-based imaging methods of the kidney-recent developments","volume":"90","author":"Correas","year":"2016","journal-title":"Kidney Int."},{"key":"2021113010580956800_B48","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"2021113010580956800_B49","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal M","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113010580956800_B50","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ndt\/gfv456","article-title":"Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"2021113010580956800_B51","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/jama.2014.6634","article-title":"Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality","volume":"311","author":"Coresh","year":"2014","journal-title":"JAMA"},{"key":"2021113010580956800_B52","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/ckj\/sfw071","article-title":"Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: why to measure glomerular filtration rate with iohexol?","volume":"9","author":"Delanaye","year":"2016","journal-title":"Clin. Kidney J."},{"key":"2021113010580956800_B53","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/ckj\/sfw070","article-title":"Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: How to measure glomerular filtration rate with iohexol?","volume":"9","author":"Delanaye","year":"2016","journal-title":"Clin. Kidney J."},{"key":"2021113010580956800_B54","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.amjmed.2016.08.019","article-title":"Creatinine clearance is not equal to glomerular filtration rate and cockcroft-gault equation is not equal to CKD-EPI collaboration equation","volume":"129","author":"Fernandez-Prado","year":"2016","journal-title":"Am. J. Med."},{"key":"2021113010580956800_B55","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"2021113010580956800_B56","doi-asserted-by":"crossref","first-page":"F647","DOI":"10.1152\/ajprenal.00090.2011","article-title":"Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy","volume":"302","author":"Sanchez-Ni\u00f1o","year":"2012","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2021113010580956800_B57","article-title":"Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis","volume-title":"UpToDate","author":"Mann","year":"2015"},{"key":"2021113010580956800_B58","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1193032","article-title":"Association of trypanolytic ApoL1 variants with kidney disease in African Americans","volume":"329","author":"Genovese","year":"2010","journal-title":"Science"},{"key":"2021113010580956800_B59","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1056\/NEJMoa020549","article-title":"Nephron number in patients with primary hypertension","volume":"348","author":"Keller","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"2021113010580956800_B60","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/ki.2012.263","article-title":"Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans","volume":"83","author":"Lipkowitz","year":"2013","journal-title":"Kidney Int."},{"key":"2021113010580956800_B61","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3390\/jcm4061325","article-title":"Horizon 2020 in diabetic kidney disease: the clinical trial pipeline for add-on therapies on top of renin angiotensin system blockade","volume":"4","author":"Perez-Gomez","year":"2015","journal-title":"J. Clin. Med."},{"key":"2021113010580956800_B62","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/13543784.2016.1196184","article-title":"Targeting inflammation in diabetic kidney disease: early clinical trials","volume":"25","author":"Perez-Gomez","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2021113010580956800_B63","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1681\/ASN.2014010012","article-title":"Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial","volume":"26","author":"Navarro-Gonz\u00e1lez","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113010580956800_B64","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1172\/JCI82592","article-title":"A role for genetic susceptibility in sporadic focal segmental glomerulosclerosis","volume":"126","author":"Yu","year":"2016","journal-title":"J. Clin. Invest."},{"key":"2021113010580956800_B65","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1681\/ASN.2014050469","article-title":"APOL1 risk variants are strongly associated with HIV-associated nephropathy in black South Africans","volume":"26","author":"Kasembeli","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113010580956800_B66","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1516767","article-title":"Resolution of disease phenotypes resulting from multilocus genomic variation","volume":"376","author":"Posey","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2021113010580956800_B67","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/ki.2014.361","article-title":"Genome-wide association study of kidney function decline in individuals of European descent","volume":"87","author":"Gorski","year":"2015","journal-title":"Kidney Int."},{"key":"2021113010580956800_B68","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ki.2015.28","article-title":"Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management\u2013A KDIGO consensus report","volume":"88","author":"Eckardt","year":"2015","journal-title":"Kidney Int."},{"key":"2021113010580956800_B69","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113010580956800_B70","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/ckj\/sfv075","article-title":"A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study","volume":"8","author":"Rojas-Rivera","year":"2015","journal-title":"Clin. Kidney J."},{"key":"2021113010580956800_B71","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/ckj\/sfv090","article-title":"A circulating permeability fac tor in focal segmental glomerulosclerosis: the hunt continues","volume":"8","author":"Wada","year":"2015","journal-title":"Clin. Kidney J."},{"key":"2021113010580956800_B72"},{"key":"2021113010580956800_B73","first-page":"gfw337","article-title":"Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis","author":"Siwy","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"2021113010580956800_B74","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"2021113010580956800_B75","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/ckj\/sfv004","article-title":"The intestine and the kidneys: a bad marriage can be hazardous","volume":"8","author":"Vanholder","year":"2015","journal-title":"Clin. Kidney J."},{"key":"2021113010580956800_B76","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/ckj\/sfv155","article-title":"Omics databases on kidney disease: where they can be found and how to benefit from them","volume":"9","author":"Papadopoulos","year":"2016","journal-title":"Clin. Kidney J."},{"key":"2021113010580956800_B77","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1042\/CS20150403","article-title":"Vascular growth factors play critical roles in kidney glomeruli","volume":"129","author":"Gnudi","year":"2015","journal-title":"Clin. Sci. (Lond.)"},{"key":"2021113010580956800_B78","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1042\/CS20140075","article-title":"Role of the potassium channel KCa3.1 in diabetic nephropathy","volume":"127","author":"Huang","year":"2014","journal-title":"Clin. Sci. (Lond.)"},{"key":"2021113010580956800_B79","doi-asserted-by":"crossref","first-page":"14518","DOI":"10.1073\/pnas.0903458106","article-title":"Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels","volume":"106","author":"Grgic","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113010580956800_B80","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1042\/CS20130412","article-title":"Integrin-linked kinase plays a key role in the regulation of angiotensin II-induced renal inflammation","volume":"127","author":"Alique","year":"2014","journal-title":"Clin. Sci. (Lond.)"},{"key":"2021113010580956800_B81","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1681\/ASN.2015080898","article-title":"Mitogen-activated protein kinase 14 promotes AKI","volume":"28","author":"Ortiz","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113010580956800_B82","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nm.2629","article-title":"Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis","volume":"18","author":"Sugimoto","year":"2012","journal-title":"Nat. Med."},{"key":"2021113010580956800_B83","doi-asserted-by":"crossref","first-page":"F1329","DOI":"10.1152\/ajprenal.00487.2016","article-title":"Downregulation of kidney protective factors by inflammation: role of transcription factors and epigenetic mechanisms","volume":"311","author":"Ruiz-Andres","year":"2016","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"2021113010580956800_B84","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1242\/dmm.024455","article-title":"Histone lysine crotonylation during acute kidney injury in mice","volume":"9","author":"Ruiz-Andres","year":"2016","journal-title":"Dis. Model Mech."},{"key":"2021113010580956800_B85","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1681\/ASN.2015080910","article-title":"Inhibition of bromodomain and extraterminal domain family proteins ameliorates experimental renal damage","volume":"28","author":"Suarez-Alvarez","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113010580956800_B86","doi-asserted-by":"crossref","first-page":"12024","DOI":"10.1073\/pnas.1305538110","article-title":"Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury","volume":"110","author":"Linkermann","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113010580956800_B87","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1681\/ASN.2015121376","article-title":"Ferroptosis, but not necroptosis, is important in nephrotoxic folic acid-induced AKI","volume":"28","author":"Martin-Sanchez","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113010580956800_B88","doi-asserted-by":"crossref","first-page":"16836","DOI":"10.1073\/pnas.1415518111","article-title":"Synchronized renal tubular cell death involves ferroptosis","volume":"111","author":"Linkermann","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113010580956800_B89","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/ckj\/sfu118","article-title":"CKD hotspots around the world: where, why and what the lessons are. A CKJ review series","volume":"7","author":"Mart\u00edn-Cleary","year":"2014","journal-title":"Clin. Kidney J."},{"key":"2021113010580956800_B90","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ckj\/sfu124","article-title":"Chronic kidney disease (CKD) in disadvantaged populations","volume":"8","author":"Garcia-Garcia","year":"2015","journal-title":"Clin. Kidney J."},{"key":"2021113010580956800_B91","first-page":"49","article-title":"Multiple socioeconomic deprivation and impact on survival in patients with primary glomerulonephritis","volume":"10","author":"McQuarrie","year":"2017","journal-title":"Clin. Kidney J."},{"key":"2021113010580956800_B92","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfw149","article-title":"Does wealth make health? Cherchez la renal replacement therapy","author":"Sanchez-Ni\u00f1o","year":"2017","journal-title":"Clin. Kidney J. 10, 45\u201348"},{"key":"2021113010580956800_B93","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/M13-2453","article-title":"Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline","volume":"160","author":"Tonelli","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"2021113010580956800_B94","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/S0140-6736(15)00418-3","article-title":"The double challenge of resistant hypertension and chronic kidney disease","volume":"386","author":"Rossignol","year":"2015","journal-title":"Lancet"},{"key":"2021113010580956800_B95","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010580956800_B96","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/ckj\/sfv088","article-title":"Haemodialysate: long neglected, difficult to optimize, may modify hard outcomes","volume":"8","author":"Perez-Gomez","year":"2015","journal-title":"Clin. Kidney J."},{"key":"2021113010580956800_B97","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/ckj\/sfw028","article-title":"Therapeutic variability in adult minimal change disease and focal segmental glomerulosclerosis","volume":"9","author":"Fernandez-Juarez","year":"2016","journal-title":"Clin. Kidney J."},{"key":"2021113010580956800_B98","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/ckj\/sfv038","article-title":"A neglected issue in dialysis practice: haemodialysate","volume":"8","author":"Basile","year":"2015","journal-title":"Clin. Kidney J."},{"key":"2021113010580956800_B99","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/ckj\/sfv057","article-title":"Optimizing haemodialysate composition","volume":"8","author":"Locatelli","year":"2015","journal-title":"Clin. Kidney J."},{"key":"2021113010580956800_B100","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.kint.2016.09.009","article-title":"Understanding kidney care needs and implementation strategies in low- and middle-income countries: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"90","author":"Jha","year":"2016","journal-title":"Kidney Int."},{"key":"2021113010580956800_B101","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"GBD 2015 Mortality and Causes of Death Collaborators","year":"2016","journal-title":"Lancet"},{"key":"2021113010580956800_B102","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ccl.2016.08.010","article-title":"Innovative approaches to hypertension control in low- and middle-income countries","volume":"35","author":"Vedanthan","year":"2017","journal-title":"Cardiol. Clin."},{"key":"2021113010580956800_B103","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/clpt.2011.173","article-title":"From treating complex coronary artery disease to promoting cardiovascular health: therapeutic transitions and challenges, 2010-2020","volume":"90","author":"Kovacic","year":"2011","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/131\/14\/1617\/450175\/cs-2016-0395c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/131\/14\/1617\/450175\/cs-2016-0395c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:48:01Z","timestamp":1719276481000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/131\/14\/1617\/71981\/Translational-science-in-chronic-kidney-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,30]]},"references-count":103,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2017,7,15]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20160395","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,30]]}}}